Photocure hosts lunch presentation Monday 28 March to present opportunities for Lumacan through agreement with Salix
Published: 17 March 2011Medical congresses & eventsPartnership News & Expansion
<div>Photocure, the Norwegian specialty pharmaceutical company focused in dermatology and cancer, is pleased to invite to a lunch presentation on Monday 28 March 2011 to further present the opportunitites for Lumacan through the license agreement with Salix Pharmaceticals Inc.</div> <div>The CEO of Salix, Carolyn Logan, and the VP of R&D of Salix, Bill Forbes, will present Salix' plans for development and commercialization of Lumacan, as well as how they perceive the market potential for Lumacan.</div> <div>The presentation will be held at Shippingklubben, Haakon VIIs gate 1, Oslo.</div> <div>Lunch is served from 11:15 am CET, the presentations start at 11:30 and the session is expected to close at 01:00 pm CET.</div> <div>The program for is as follows:</div> <div>· Welcome remarks and introduction by CEO of Photocure, Kjetil Hestdal</div> <div>· Presentation of Salix, by CEO of Salix, Carolyn Logan</div> <div>· US colon cancer market and the Lumacan opportunity, by VP of R&D Salix, Bill Forbes</div> <div>· Q&A and closing remarks</div> <div> <p>Please register your attendance at Photocure by Friday 25 March 1pm. Contact person: Grete Faye-Schjøll (e-mail: <a href="mailto:gfs@photocure.no" target="_blank">gfs@photocure.no</a> / phone +47 22 06 22 10 / fax +47 22 06 22 18).</p></div> <div><b>For more information, please contact:</b></div> <div>Christian Fekete</div> <div>CFO </div> <div>Photocure ASA</div> <div>Tel: + 47 916 42 938, E-mail: <a href="mailto:cf@photocure.no" target="_blank">cf@photocure.no</a> </div> <div>This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)</div>